SCHEMBL1638665

SCHEMBL1638665

OC(c1ccccn1)c1cccc(-c2ccccc2)c1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
FFAR1 O14842 2/20 0.36
LMNA P02545 3/20 0.36
HPGD P15428 3/20 0.36
HTT P42858 3/20 0.36
TSHR P16473 2/20 0.36
MAPK1 P28482 2/20 0.36
ALOX15 P16050 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
SLC6A2 P23975 1/20 0.36
GAA P10253 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
PTGER1 P34995 4/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12646989 0.83 SCN8A (0.39) MAPTMAPK1SLC6A2ALDH1A1KDM4E
SCHEMBL1639177 0.83 LMNA (0.42) MAPTFFAR1LMNAHPGDHTT
SCHEMBL1643988 0.81 MGAM (0.46) FFAR1LMNAHPGDRXRARXRB
SCHEMBL1637949 0.79 MAPK1 (0.46) MAPTFFAR1LMNAHPGDHTT
SCHEMBL1638059 0.79 MGAM (0.47) FFAR1RXRARXRBRXRGGAA
SCHEMBL27794252 0.76 MGAM (0.41) MAPTFFAR1LMNAHPGDHTT
SCHEMBL1638313 0.76 LMNA (0.39) FFAR1LMNAHPGDHTTTSHR
SCHEMBL27794250 0.73 PTGER1 (0.48) FFAR1LMNAHPGDRXRARXRB
SCHEMBL12725979 0.72 ADORA3 (0.50) MAPTLMNAHTTSMN1; SMN2RXRA
SCHEMBL1637564 0.72 ADORA3 (0.44) MAPTLMNAHPGDHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541521-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
US-8541521-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
EP-2493933-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056424-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098427-A1 Catalyst Compounds And Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098427-A1 Catalyst Compounds And Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098427-A1 Catalyst Compounds And Use Thereof THEM6, OPRM1, NOTUM MAPT 1035/4885FFAR1 254/4885LMNA 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.